Document is current
Any future updates will be listed below
-
Authors
Perez de Isla, Leopoldo https://orcid.org/0000-0002-9706-7783
Liberopoulos, Evangelos
Dovizio, Melania
Veronesi, Chiara
Degli Esposti, Luca
Zambon, Alberto
-
Funding
Funding for this research was provided by:
Servier
- License Information
-
More Information
Article History
Received: 22 March 2024
Accepted: 29 May 2024
First Online: 4 July 2024
Declarations
:
: Leopoldo Perez de Isla reports research grants, speaker fees and consultant fees from Servier, Sanofi, Amgen, Daiichi-Sankyo and Merk. Evangelos Liberopoulos reports grants from Hellenic Atherosclerosis Society; personal fees and non-financial support from Amgen, personal fees from Sanofi, personal fees from Lilly, personal fees from Bayer, personal fees from Novo Nordisk, grants and personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Servier, grants and personal fees from Viatris, outside the submitted work. Alberto Zambon reports speaker fees and consultant fees from Amgen, Amarin, Amryt, AlfaSigma, Abbott, Viatris, Novartis, Sanofi, Sobi, Servier, Daiichi Sankyo. Melania Dovizio, Chiara Veronesi, Luca Degli Esposti have no competing interests to disclose.
: The study was approved by the following institutional review boards (or ethics committees): Comitato Etico Regionale Liguria (protocol number 0179046/2020, approval date 14/06/2021); Comitato Etico “Lazio 2” (protocol number 0216084/2020, approval date 16/12/2020); Comitato Indipendente di Etica Medica (protocol number 48144, approval date 28/05/2021); Comitato Etico per le Sperimentazioni Cliniche (CESC) della Provincia di Vicenza (protocol number 1627, approval date 28/10/2020); Comitato etico interprovinciale Area I (protocol number 63/CE/20, approval date 3/12/2020); Comitato Etico Inter-aziendale Campania Sud (protocol number 51, approval date 02/09/2020); Comitato Etico “Lazio 1” (protocol number 1079/CE Lazio 1, approval date 23/09/2020); Comitato Etico Inter-aziendale Campania Sud (protocol number 64, approval date 03/11/2020); Comitato Etico per la Sperimentazione Clinica della provincia di Venezia e IRCCS S.Camillo (28/07/2020); Comitato Etico per le province di L’Aquila e Teramo (protocol number 11, approval date 24/03/2021); Comitato Etico Regionale Umbria (protocol number 19414/20/ON, approval date 16/09/2020); Comitato Etico “Lazio 1” (protocol number 1080/CE Lazio 1, approval date 23/09/2020). The authors affialiated with CliCon S.r.l., Società Benefit-Health were authorized for data treatment and analysis by the involved healthcare entities (Local Health Units).
